Bayer Sees Flat 2026 Profits Amid Roundup Settlement Efforts

Bayer AG forecast little change in profit and sales in 2026 as the German agriculture and health company grapples with generic competition for its blockbuster blood thinner and continued uncertainty over mass US litigation tied to its Roundup weed killer. The shares fell.

Adjusted earnings before interest, taxes, depreciation and amortization will probably reach between €9.6 billion and €10.1 billion ($11.1 billion to $11.7 billion) this year on a currency-adjusted basis, the company said Wednesday. That compares with a €9.75 billion average estimate from analysts and last year’s decline to €9.67 billion.